Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV-6: Fluvoxamine in mild to moderate COVID-19
NCT05894564Phase 3Completed
- Start
- Aug 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluvoxamine in coronavirus disease 2019 (COVID-19). Started Aug 2022; status: completed.
02
Drugs
fluvoxamine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05894564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05894564.